Articles

In this fourth installment, Shubham Pant, MD, along with Tanios Bekaii-Saab, MD, discuss the key side effects seen in clinical trials of first-line treatments for patients with pancreatic cancer. Read More ›

Zongertinib, a HER2 TKI, demonstrated clinically meaningful activity and tolerability in patients with NSCLC with and without brain metastases harboring a HER2 mutation.

Read More ›

In this third installment, Michael Pishvaian, MD, PhD, and Tanios Bekaii-Saab, MD, discuss why median progression-free survival is so important when considering the various transformational trials in pancreatic cancer. Read More ›

In this second installment, Shubham Pant, MD, along with Tanios Bekaii-Saab, MD, discuss various first-line treatments for metastatic pancreatic ductal adenocarcinoma from the MPACT, PRODIGE-4, and NAPOLI 3 trials. Read More ›

In this first installment, Shubham Pant, MD, along with Tanios Bekaii-Saab, MD, discuss how patients are evaluated for pancreatic cancer. Read More ›

Lung cancer is the top cause of cancer death and the third most common cancer type in the United States, according to the National Cancer Institute. With an estimated 234,580 new cases of lung and bronchus cancer to be diagnosed in 2024 alone, this cancer will almost certainly affect a portion of your patients. Test your knowledge of this disease here. Read More ›

Breast cancer is the second most common cancer among women after skin cancer, according to the National Cancer Institute. In fact, in 2024 an estimated 310,720 cases will be diagnosed in women, representing 15.5% of all new cancers diagnosed that year, and 42,250 women with breast cancer will die. Test your knowledge of this widespread cancer. Read More ›